Pfizer has stumbled with the reveal of new data on the efficacy of its oral CDK 4/6 inhibitor Ibrance (palbociclib) in combination with AstraZenenca’s Faslosdex (fulvestrant) as the company confirmed the therapy had failed to meet its Phase 3 secondary endpoint of overall survival in breast cancer.
Reageer